NCT07075250 2025-07-20
RIFOC003
Peking University People's Hospital
Phase 4 Not yet recruiting
Clinical Trials
13 trialsNCT06660511 2024-10-28
Exploratory Study on the Safety and Efficacy of Disitamab Vedotin in Combination with Anlotinib Hydrochloride for the Treatment of HER-2-expressing Recurrent Platinum-resistant Ovarian Cancer.
Second Xiangya Hospital of Central South University
Phase EARLY_PHASE1 Recruiting
NCT05817214 2024-04-19
Cadonilimab Plus Anlotinib for R/M/P Cervical Cancer
Zhongnan Hospital
Phase 2 Recruiting
NCT02584478 2023-11-08
AL3818
Advenchen Laboratories, LLC
Phase 3 Unknown
NCT05736952 2023-05-11
Oral Topotecan Combined With Anlotinib in Patients With Platinum-resistant Recurrent Ovarian Cancer
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Phase 2 Withdrawn
NCT05130515 2023-01-31
CC-ANNIE
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Completed
NCT05311579 2022-04-13
Niraparib Plus Anlotinib for Recurrent Ovarian Cancer
Peking Union Medical College Hospital
Phase 2 Unknown
NCT04731038 2021-09-17
Combination Therapy for First Line Treatment of Advanced Cervical Cancer
Ruijin Hospital
Phase 1 Unknown
NCT04376073 2020-11-25
ANNIE
Sun Yat-sen University
Phase 2 Unknown
NCT04566952 2020-10-30
ANLOLA
Jiangsu Cancer Institute & Hospital
Phase 2 Unknown
NCT04157491 2019-11-08
Anti-PD-1 Antibody Combined With Anlotinib in the Treatment of Endometrial Cancer
Sun Yat-sen University
Phase 1/2 Unknown
NCT02558348 2019-06-19
AL3818
Advenchen Laboratories, LLC
Phase 1/2 Terminated
NCT03924882 2019-04-23
Anlotinib for Patients With Platinum Resistant or Refractory Ovarian Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Unknown